Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

BETHESDA, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2025, and provided a corporate update. Important highlights during the quarter included earlier-than- anticipated completion of target enrollment for the company's Phase 1b study evaluating le ...